GlobeNewswire: Celldex Therapeutics, Inc. Contains the last 10 of 241 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:10:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/08/2843022/0/en/Celldex-Therapeutics-to-Participate-in-the-Leerink-Partners-Global-Biopharma-Conference.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference2024-03-08T12:00:00Z<![CDATA[HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/03/05/2840644/0/en/Celldex-Therapeutics-to-Present-at-TD-Cowen-s-44th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference2024-03-05T15:30:00Z<![CDATA[HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET.]]>https://www.globenewswire.com/news-release/2024/03/05/2840626/0/en/Celldex-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares2024-03-05T15:10:49Z<![CDATA[HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. All of the shares sold in the offering were sold by Celldex. The gross proceeds to Celldex from this offering were approximately $460.5 million, excluding underwriting discounts and commissions and other offering-related expenses.]]>https://www.globenewswire.com/news-release/2024/03/01/2838543/0/en/Celldex-Therapeutics-Announces-Pricing-of-Upsized-400-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock2024-03-01T02:14:47Z<![CDATA[HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, of approximately $400.4 million, excluding underwriting discounts and commissions and other offering-related expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/02/28/2837393/0/en/Celldex-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics Announces Proposed Public Offering of Common Stock2024-02-28T21:01:00Z<![CDATA[HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock are being offered by the Company. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2024/02/26/2835014/0/en/Celldex-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=18430Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update2024-02-26T12:01:00Z<![CDATA[- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 -- Enrollment nearing completion in Phase 2 CIndU study; Data expected 2H 2024 -- Phase 2 PN study expected to start in early 2024; Positive Phase 1 PN data reported in oral presentation at WCI 2023 -]]>https://www.globenewswire.com/news-release/2024/02/24/2834744/0/en/Celldex-Therapeutics-Presents-Positive-12-Week-Results-from-Barzolvolimab-Phase-2-Study-in-Chronic-Spontaneous-Urticaria.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria2024-02-24T19:05:00Z<![CDATA[- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 am ET-]]>https://www.globenewswire.com/news-release/2024/02/06/2824705/0/en/Celldex-to-Participate-in-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html?f=22&fvtc=4&fvtv=18430Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference2024-02-06T21:01:00Z<![CDATA[HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/05/2823506/0/en/Celldex-Announces-Upcoming-Presentation-of-Barzolvolimab-Phase-2-Results-in-Chronic-Spontaneous-Urticaria-at-AAAAI-2024.html?f=22&fvtc=4&fvtv=18430Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 20242024-02-05T13:01:00Z<![CDATA[HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2024 being held in Washington, DC on February 23-26, 2024. Abstracts will be available on the meeting website today, February 5, 2024.]]>https://www.globenewswire.com/news-release/2023/11/27/2786532/0/en/Celldex-Therapeutics-to-Present-at-6th-Annual-Evercore-ISI-HealthCONx-Conference.html?f=22&fvtc=4&fvtv=18430Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference2023-11-27T21:15:00Z<![CDATA[HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28th at 5:05 pm ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.]]>